Low-dose interleukin-2 combined with thalidomide for a severe cutaneous immune-related adverse event associated with PD-1/CTLA-4 bispecific antibody therapy: a case report.
Immune checkpoint inhibitors (ICIs), including novel bispecific antibodies targeting programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), have expanded therapeutic options but have also increased the incidence and complexity of immune-related adverse events (irAEs). Low-dose...